Darborn
☆    

Taiwan,
2025-10-14 07:34
(251 d 01:22 ago)

Posting: # 24450
Views: 3,079
 

 long half-life AUC0-t or AUC0-72 [NCA / SHAM]

Hi everyone,

When calculating AUC0–∞, I know some regulatory agencies use extrapolation while others use the actual value. For a long half-life pro­duct truncated at 72 hours, should I use AUC0–t or AUC0–72 for bioequivalence assessment? :confused: I think these two value may differ when 72h has a LLOQ.

Thank you!


Edit: Category changed; see also this post #1[Helmut]
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2025-10-14 12:30
(250 d 20:25 ago)

@ Darborn
Posting: # 24451
Views: 2,665
 

 IR with t½ ≥ 24 h

Hi Darborn,

❝ When calculating AUC0–∞, I know some regulatory agencies use extrapolation while others use the actual value. For a long half-life pro­duct truncated at 72 hours, should I use AUC0–t or AUC0–72 for bioequivalence assessment? :confused:

If it is an IR-product with a half life ≥ 24 h, AUC0–72 (see this article about ICH M13A and the linked references).

If t½ < 24 h, the primary metric is AUC0–t. You have to estimate AUC0– as well but only to assess the extrapolated fraction (AUC0–t should cover ≥ 80 % of AUC0– in ≥ 80 % of observations).

❝ I think these two value may differ when 72h has a LLOQ.

Of course. See this presentation (slides 19–24).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Darborn
☆    

Taiwan,
2025-10-16 08:05
(249 d 00:51 ago)

@ Helmut
Posting: # 24459
Views: 2,563
 

 IR with t½ ≥ 24 h

Thank you Helmut,

What I really mean is if the product has long half-life, Will it be acceptable using AUC0-72 with extrapolation with some LLOQ at 72h.
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2025-10-16 10:13
(248 d 22:43 ago)

@ Darborn
Posting: # 24460
Views: 2,543
 

 long half life product?

Hi Darborn,

❝ What I really mean is if the product has long half-life,…

Not sure what you mean by that. The drug may have a long half life.

Or are you talking about a controlled release product (flip-flop PK: \(\small{k_\text{a}\le k_\text{el}}\))? In this case the later part of the profile represents absorption, we are interested in comparing formulations. For such products AUC0–72 is not acceptable.* Instead, AUC0– must be assessed additionally to AUC0–t. Depending on the product’s release characteristics you may have to sample ≥ 72 h in order to get a reliable estimate of the apparent (here absorption!) half life.

❝ … Will it be acceptable using AUC0-72 with extrapolation with some LLOQ at 72h.

For IR products yes. Read slide 23 of my presentation again. That’s ElMaestro’s option 1b with lin/log extrapolation and the one I’m using in my studies.


  • European Medicines Agency (CHMP/EWP). Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms. London, 20 November 2014. Online.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Darborn
☆    

Taiwan,
2025-10-17 07:16
(248 d 01:40 ago)

@ Helmut
Posting: # 24463
Views: 2,472
 

 long half life product?

Thank you Helmut, I get it :-D
ElMaestro
★★★

Denmark,
2025-10-15 19:41
(249 d 13:15 ago)

@ Darborn
Posting: # 24457
Views: 2,633
 

 long half-life AUC0-t or AUC0-72

Hi Darborn,

❝ When calculating AUC0–∞, I know some regulatory agencies use extrapolation while others use the actual value.


I am not sure I understood this sentence.

❝ For a long half-life pro­duct truncated at 72 hours, should I use AUC0–t or AUC0–72 for bioequivalence assessment? :confused: I think these two value may differ when 72h has a LLOQ.


When you intend to evaluate BE by truncated AUC, like AUC0-72 then you have some options, and I imagine this is the reason you ask.

1. For a profile with BLQs at the end you can do
1a. Let AUC0-72=AUCt
1b. Extrapolation, which can be linear or log-based from the least measurable points in the elim phase.
I have seen both 1a and 1b accepted recently. Funnily enough if you do linear extrapolation, you may get negative concentrations on the extrapolated part depending on how ugly your data is. I have seen it accepted nonetheless.
2. For a profile where the last sample is not exactly 72hrs but measurable (ambulatory subjects are particularly unreliable when it comes to showing up on time), you can do:
2a. Let AUC0-72=AUCt
2b. Inter- or extrapolation, which can be linear or log-based from the least measurable points in the elim phase.
This also seems to be accepted as far as I can tell.

At the end of the day, in BE we do not really care much if a profile can be said to be biased, rather we just want T/R estimates to be unbiased or at least have no arguments in favour of bias on the ratio.
So, as long as all profiles are treated in the same fashion, it is difficult for a regulator to argue that the ratio end up being biased. Therefore the various flavours and colors of AUC0-72 are accepted even if something looks odd in someone's opinion from the perspective of a single profile.

Pass or fail!
ElMaestro
Darborn
☆    

Taiwan,
2025-10-16 08:00
(249 d 00:55 ago)

@ ElMaestro
Posting: # 24458
Views: 2,547
 

 long half-life AUC0-t or AUC0-72

So the point is to use the same method in treating all profiles. Thank you ElMaestro.
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
163 visitors (0 registered, 163 guests [including 43 identified bots]).
Forum time: 08:56 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5